



In all correspondence concerning this questionnaire, please quote this nine-digit reference number

Collected under the authority of the Statistics Act, Revised Statutes of Canada, 1985, Chapter S19.

Si vous péférez ce questionnaire en français, veuillez appeler un des bureaux de Statistisque Canada inscrits à la page 11.

 ${f G}$

Please correct name and address, if necessary

Purpose

Statistics Canada is undertaking this survey to measure and develop a better understanding of the emerging contribution of biotechnology to the Canadian economy. The information from the survey can be used by businesses for market analysis, by trade associations to study performance and other characteristics of their industries, by government to develop national and regional economic policies, and by other users involved in research or policy making. Statistics Canada will create a database combining individual survey responses with existing Revenue Canada and Statistics Canada data records.

Authority

Collected under authority of Statistics Act, Revised Statutes of Canada, 1985, Chapter S19

Confidentiality

Statistics Canada is prohibited by law from publishing or releasing, in any manner, any statistics which would divulge information obtained from this survey relating to any identifiable business. The data reported on the survey questionnaire will be treated in strict confidence, used for statistical purposes and released in aggregate form only.

Questions?

If you require assistance in the completion of this questionnaire or have any questions regarding this survey, please phone one of the Statistics Canada regional office listed on page 11.

Survey Contact

Please indicate the name of the person completing this form so we know who to contact should we have questions about this report.

Name	Title
Telephone Number	Fax Number

Company Information

Please report data for 1996 or the latest fiscal year available. Exclude GST and all other taxes collected by you for remittance to a government agency. Do not include sales and operations of your subsidiaries located abroad.

	Year	Amount
A1. Operating revenue (\$000)	A1A	A1B
A2. Sales to other provinces (as % of operating revenue)		A2A %
A3. Exports to the United States and Mexico (as % of operating revenue)		A3A %
A4. Exports to other countries in rest of World (as % of operating revenue)		A4A %
A5. Number of employees (average for the year)		A5A
a) Full time		
b) Part time		A5B
c) Contract		A5C
d) Total		A5D
AQ Number of employees bullets be dependent.	Total	Working with biotechnologie
Ab. Number of employees, by level of education	A6A	A6D
b) College graduates	A6B	A6E
c) All other employees	A6C	A6F

5-4700-40.1: 1996-12-16 SQC/SAT 465-75092

Canadä



Use of Biotechnologies

B1 For each item or biotechnology listed below, please indicate ($\sqrt{}$) which description best reflects its function within your business activities.

		1	UTILIZATION
Biotechnology	Currently Used in operations	Approximate number of years in use	Research stage
SELECTION AND/OR MODIFICATION OF BIOLOG	ICAL MATERIAL		
Recombinant DNA	B1AA Yes	B1AB	B1AC
Procedure used to join together DNA segments outside a cell. Also referred to as genetic engineering.	○ No ▶		
Antibodies / antigens	B1BA Yes	B1BB	B1BC
Proteins produced in the body in response to the introduction of foreign molecules called antigens.	○ No ▶		
Peptide synthesis	B1CA Yes	B1CB	B1CC
Procedure to link two or more amino acids joined by a linkage called a peptide bond.	🔿 No 🕨		
Rational drug design	B1DA Yes	B1DB	B1DC
Analysis of the structures of active sites of enzymes and receptors in order to design pharmacologically active synthetic molecules that will fit these analyzed structures.	○ No ▶		
Monoclonal antibodies	B1EA Yes	B1EB	B1EC
A monoclonal antibody is a highly specific antibody which is derived from one line of cells and which recognizes only one specific complimentary antigen.	🔿 No 🕨		
Gene probe	B1FA Yes	B1FB	B1FC
A section of DNA of known structure or function which is marked with a radioactive isotope, dye or enzyme so that it can be used to detect the presence of specific sequences of bases in another DNA molecule	○ No ▶		
Gene therapy	B1GA Yes	B1GB	B1GC
Replacement of a defective gene in an organism suffering from a genetic disease.	🔿 No 🕨		-
DNA amplification	B1HA Yes	B1HB	В1НС
Process of increasing the number of copies of a particular gene or chromosomal sequence.	○ No ▶		
ENVIRONMENTAL BIOTECHNOLOGIES	P1IA	R1IR	RUC
Bioaugmentation Is the process of increasing the efficiency of the naturally	Yes		
specific compounds. This is usually achieved by adding nutrients, oxygen or water.	○ No ▶		
Bioremediation Is a process that involves the use of naturally occurring or	B1JA Ves	B1JB	B1JC
genetically modified micro-organisms to breakdown or degrade hazardous substances into less hazardous or non-toxic substances.	○ No ▶		
Bio-reactors	DIKA Yes	B1KB	В1КС
Are enclosed containers in which micro-organisms are maintained under controlled conditions for the purpose of creating or destroying specific compounds.	○ No ▶		
Phytoremediation	B1LA Yes	B1LB	BILC
Is the use of vegetative species for the purposes of site remediation.	○ No ▶		
Biological gas cleaning	B1MA Yes	B1MB	B1MC
Is the use of micro-organisms to break-down or degrade hazardous substances in a gas stream into less hazardous			

Purposes for Using Biotechnologies

Part of the product sold	Pollution			
productiona	control system	Plan to use within next	No plans	s to use
		2 years	No application	Not cost effective
B1AE	B1AF			
0	0			
		B1AG	2	3
B1BE	B1BF		Ŭ	
		B1BG		
		1 ()	2 🔿	3 🔾
B1CE	B1CF			
		B1CG	2 ()	3 (
B1DE	B1DF			
0	0			
			2	з ()
B1EE	B1EF		11	
		B1EG		
D1EE	D1EE		2	3 ()
		B1FG	2	3
B1GE	B1GF		Ŭ	
		B1GG		
		1 🔿	2 🔿	3 🔾
		B1HG	2	3
B1IE	B1IF			
		B1IG		
B1JE	B1JF		2 ()	3 ()
0	0		,	
		B1JG	2	3 ()
В1КЕ	B1KF			-
		B1KG		
B11 F	B1I F		2 🔿	3 🔾
		B1LG 1	2	3
B1ME	B1MF			\bigcirc
	B1BE	B1BE B1BF B1CE B1CF B1DE B1DF B1EE B1EF B1FE B1FF B1FE B1FF B1FE B1FF B1FE B1FF B1FE B1GF B1FE B1GF B1HE B1HF B1HE B1HF B1HE B1JF B1HE B1JF B1KE B1KF B1LE B1MF B1ME B1MF	B1AG 1 B1BE B1BF B1CE B1CF B1CE B1CF B1DE B1DF B1DE B1DF B1DE B1DF B1DE B1CF B1DE B1CF B1DE B1DF B1DE B1CF B1DE B1EF B1EE B1EF B1FE B1FF B1FE B1FF B1FE B1GF B1FE B1GF B1FE B1GF B1GE B1GF B1HE B1HF B1GE B1GF B1GE B1GF B1GE B1GF B1GE B1GF B1GE B1GF B1GE B1GF B1GE B1GE B1GE	BIAG 1 2 BIDE BIBF BIBG 2 BICE BIOF BIGG 2 BIDE BIOF BIOG 2 BIDE BIOF BIOF 2 BIDE BIOF BIOG 2 BIDE BIOF BIG 2 BIDE BIOF BIG 2 BIEE BIFF BIG 2 BIFE BIHF BIG 2 1 BIFE BIFF BIG 2 1 BIFE BIFF BIG 2 1 BIFE BIFF BIG 2 1 BIFF BIG 1 2 1 BIFF BIG 2

Use of Biotechnologies - Continued

B1 For each item or biotechnology listed below, please indicate ($\sqrt{}$) which description best reflects its function within your business activities. – Continued

			UTILIZATION
Biotechnology	Currently used in operations	Approximate number of years in use	Research stage
CULTURE AND/OR USE OF BIOLOGICAL MATER	IAL		
Tissue culture	B1NA Yes	B1NB	BINC
Propagation or growth of cells which are isolated from organisms in a nutrient medium in a laboratory environment.	○ No 🕨		
Somatic embryo-genesis	B1OA Yes	B1OB	B1OC
Propagation of genetically desirable plant and tree lineages by tissue culture methods.	○ No 🕨		
<u>Bio-pesticide</u>	B1PA Ves	B1PB	B1PC
Biological pest control through the use of naturally occurring microbes or bacteria.	○ No 🕨		
Classical/traditional breeding	B1QA Yes	B1QB	B1QC
Genetic improvement of animals or plants by breeding selected individuals.	○ No 🕨		
Bioprocessing	B1RA Yes	B1RB	B1RC
Production stages that include fermentation, recovery, and purification.	🔿 No 🕨		
<u>Bio sensing</u> Use of a biological molecule e.g. enzymes, antibodies in	B1SA Ves	B1SB	B1SC
conjunction with a transducer to low level detection of substances such as sugars and proteins in body fluids, pollutants in water etc.	○ No 🕨		
Bio-bleaching_	B1TA Yes	B1TB	B1TC
Use of micro-organisms to bleach pulp.	○ No 🕨		
Bio-leaching	B1UA Yes	B1UB	BIUC
Use of micro-organisms to leach metals from ore.	🔿 No 🕨		
Microbio-inoculants	B1VA Ves	B1VB	B1VC
Naturally occuring bacterial inoculants used to promote plant growth.	🔿 No 🕨		

If you do not use any of the biotechnologies listed above, please go to question C4, D3 and following.

Purposes for Using Biotechnologies - Continued

B1 For each item or biotechnology listed below, please indicate (√) which description best reflects its function within your business activities. – Continued

TAGE					
Part of the	Part of the	Pollution	ution Plan to use No plans	No plans to use	
production process	product sold	control system	within next 2 years	No application	Not cost effective
BIND	B1NE	BINE	1		
\bigcirc					
			B1NG	2	з ()
B1OD	B1OE	B1OF			
			B1OG 1	2	3 🔾
	В1РЕ	B1PF			
			B1PG	2	3
B1QD	B1QE	B1QF			
			B1QG 1 🔵	2	3
B1RD	B1RE	B1RF			
			B1RG	2	3 🔾
B1SD	B1SE	B1SF			
			B1SG	2	3 🔾
B1TD	BITE	B1TF			
			B1TG	2	3
B1UD	BIUE	BIUF			
			B1UG	2	3
B1VD	B1VE	B1VF			
			B1VG	2	3

Purposes for Using Biotechnologies - Continued

B2 Please indicate ($\sqrt{}$) the range that best reflects this plant's total capital investment in biotechnology equipment and software for 1996 or latest fiscal year available. Please **exclude** education and training but **include** plant modifications, construction, integration, and equipment and software purchased or developed.

Please Answer Separately for Each Functional Group.

Cost Category	Selection and/or Modification of Biological Material	Culture and/or Use of Biological Material	Environmental Biotechnologies
	B2A	B2B	B2C
Less than \$100,000	1 🔵	1 🔵	1 🔵
\$100,000 to less than \$1 million	2	2	2
\$1 million to less than \$5 million	3 🔵	3 🔵	3 🔵
\$5 million to less than \$10 million	4 🔵	4 🔿	4 🔿
\$10 million or more	5 🔵	5 🔵	5 🔵
Not applicable	6	6 🔵	6 🔵

Factors Affecting the Use of Biotechnologies

C1 Please indicate ($\sqrt{}$) any **positive factors** that have particular significance in the **decision** of your firm to use biotechnologies or biotechnology equipment.

Factors	Selection and/or Modification of Biological Material	Culture and/or Use of Biological Material	Environmental Biotechnologies
	C1A1	C1B1	C1C1
Lower production cost	\bigcirc		\bigcirc
	C1A2	C1B2	C1C2
Internal familiarity with the technology	\bigcirc		0
	C1A3	C1B3	C1C3
Develop new products or processes	0	0	0
	C1A4	C1B4	C1C4
Extend product range	\bigcirc		0
	C1A5	C1B5	C1C5
Acquire a better market position	\bigcirc		0
	C1A6	C1B6	C1C6
Increase production flexibility	0	0	0
	C1A7	C1B7	C1C7
Lower maintenance expense	\bigcirc		\bigcirc
	C1A8	C1B8	C1C8
Faster delivery time	0	0	0
	C1A9	C1B9	C1C9
Other	0	0	0

Factors Affecting the Use of Biotechnologies - Continued

C2 Please indicate ($\sqrt{}$) any difficulties that had particular significance in implementing your biotechnology processes.

Difficulties	Selection and/or Modification of Biological Material	Culture and/or Use of Biological Material	Environmental Biotechnologies
	C2A1	C2B1	C2C1
Training	0	0	0
	C2A2	C2B2	C2C2
Skill availability	0	0	0
	C2A3	C2B3	C2C3
Adaptability to other technologies		0	0
	C2A4	C2B4	C2C4
Adapting to norms and standards			
	C2A5	C2B5	C2C5
Need for advice and information	0	0	0
	C2A6	C2B6	C2C6
Increased maintenance expense	\bigcirc	\bigcirc	\bigcirc
	C2A7	C2B7	C2C7
Insufficient market for product	0	0	0
	C2A8	C2B8	C2C8
Lack of technical support from vendors	0	0	0
	C2A9	C2B9	C2C9
Regulatory constraints		\bigcirc	\circ
	C2A10	C2B10	C2C10
Other			
	C2A11	C2B11	C2C11
There were no barriers			

Factors Affecting the Use of Biotechnologies - Continued

C3 Please indicate ($\sqrt{}$) whether the adoption of biotechnologies and biotechnology equipment **led to** any of the following **results**.

	Selection and/or Modification of	Culture and/or Use of Biological Material	Environmental Biotechnologies				
Results	Biological Material	Biological Material					
	C341	C3B1	0301				
An improvement in productivity							
Lower Production Costs by Redu	Lower Production Costs by Reducing:						
	C3A2	C3B2	C3C2				
Labour requirements	0	0	0				
	СЗАЗ	СЗВЗ	C3C3				
Material consumption	0	0	0				
	C3A4	C3B4	C3C4				
Energy consumption	0	0	0				
	C3A5	C3B5	C3C5				
Product rejection rate			\bigcirc				
Other Improvements:							
	C3A6	C3B6	C3C6				
Improvement in product quality			0				
	C3A7	C3B7	C3C7				
Greater product flexibility	\circ	\circ	0				
	C3A8	C3B8	C3C8				
Improved working conditions	\bigcirc	\bigcirc	0				
	C3A9	C3B9	C3C9				
Reduced environmental damage	0	\bigcirc	0				
	C3A10	C3B10	C3C10				
Reduced skill requirements	\bigcirc	\bigcirc	0				
	C3A11	C3B11	C3C11				
Reduced capital investments		\bigcirc	0				
· · · · · · · · · · · · · · · · · · ·	C3A12	C3B12	C3C12				
Increased skill requirements			0				
	C3A13	C3B13	C3C13				
Increased capital requirements			0				
	C3A14	C3B14	C3C14				
Increased equipment utilization rate							
	C3A15	C3B15	C3C15				
Lower inventory	0	0	0				
	C3A16	C3B16	C3C16				
Other	0	<u> </u>	0				
	C3A17	C3B17	C3C17				
There were no improvements							

	Insignificant	Slightly insignificant	Moderately significant	Very significant	Crucial	Not applical
Cost-Related Problems						
High cost of biotechnology equipment - (C41)	1 🔿	2 🔿	3 🔾	4 🔾	5 🔾	6
Lack of equity capital for implementation of new biotechnology acquisition - (C42)	1 🔿	2 🔿	3 🔾	4 🔿	5 🔿	6
Lack of financial justification - (C43)	1 🔵	2 🔾	3 🔾	4 🔿	5 🔾	6 🤇
Cost of training - (C44)	1 🔵	2 🔿	3 🔾	4 🔾	5 🔿	6
Increased maintenance expenses - (C45)	1 🔵	2 🔿	3 🔿	4 🔿	5 🔿	6 🤇
Insufficient market for product - (C46)	1 🔵	2 🔿	3 🔾	4 🔿	5 🔿	6
Government regulations/standards - (C47)	1 🔿	2 🔿	з ()	4 🔿	5 🔿	6
Availability of Inputs						
Lack of equity capital for investment in biotechnologies - (C48)	1 🔵	2 🔿	3 🔾	4 🔾	5 🔿	6
Lack of outside capital for investment in biotechnologies - (C49)	1 🔿	2 🔿	3 🔾	4 🔿	5 🔿	6
Shortage of skills - (C410)	1 🔿	2 🔿	3 🔾	4 🔿	5 🔿	6
Training difficulties - (C411)	1 🔿	2 🔿	3 🔾	4 🔾	5 🔾	6
Organizational Problems						
Difficulties in introducing important changes to the organization - (C412)	1 🔿	2 🔿	з ()	4 🔿	5 🔿	6
Internal resistance to biotechnologies - (C413)	1 🔿	2 🔿	3 🔿	4 🔿	5 🔿	6 🤇
Worker resistance - (C414)	1 🔿	2 🔿	3 🔿	4 🔾	5 🔾	6
Other Problems						
Lack of scientific and technical information - (C415)	1 🔿	2 🔿	3 🔾	4 🔿	5 🔿	6
Lack of technological services (e.g. technical and scientific consulting, tests, standards) - (C416)	1 🔿	2 🔿	3	4 🔿	5 🔿	6
Lack of technical support from vendors - (C417)	1 🔵	2 🔿	3 🔿	4 🔿	5 🔿	6
Biotechnologies not sufficiently developed - (C418)	1 🔵	2 🔿	3 🔿	4 🔵	5 🔿	6
Lack of information about potential markets - (C419)	1 🔵	2 🔿	3 🔾	4 🔾	5 🔿	6
Other - (C420)	1 🔘	2 🔿	з ()	4 🔘	5 🔿	6
There were no impediments - $(C421)$	1	2	3	4	5 🔿	6

Sources of Information

D1 Please indicate ($\sqrt{}$) your principal **internal** sources of information for the adoption of biotechnologies or biotechnology equipment.

Please Answer Separately for Each Functional Group.

Internal Source	Selection and/or Modification of Biological Material	Culture and/or Use of Biological Material	Environmental Biotechnologies
Research		D1B1	D1C1
Experimental development		D1B2	D1C2
Design work	D1A3	D1B3	D1C3
Production engineering	D1A4	D1B4	D1C4
Operating staff	D1A5	D1B5	D1C5
Management	D1A6	D1B6	D1C6
Corporate Head Office	D1A7	D1B7	D1C7
Other	D1A8	D1B8	D1C8

D2 Please indicate ($\sqrt{}$) your principal **external** sources of information for the adoption of biotechnologies or biotechnology equipment.

External Source	Selection and/or Modification of Biological Material	Culture and/or Use of Biological Material	Environmental Biotechnologies
A related firm (with same parent firm)	D2A1	D2B1	D2C1
An unrelated firm		D2B2	D2C2
Federal research organizations	D2A3	D2B3	D2C3
Universities	D2A4	D2B4	D2C4
Provincial research organizations	D2A5	D2B5	D2C5
Federal information programs	D2A6	D2B6	D2C6
Research consortia	D2A7	D2B7	D2C7
Consultants and service firms	D2A8	D2B8	D2C8
Joint ventures and strategic alliances	D2A9	D2B9	D2C9
Publications	D2A10	D2B10	D2C10
Trade fairs, conferences	D2A11	D2B11	D2C11
Customer firms	D2A12	D2B12	D2C12
Supplier firms	D2A13	D2B13	D2C13
There was no significant external input	D2A14	D2B14	D2C14
Other	D2A15	D2B15	D2C15

Sources of Information - Continued

D3 How would you compare your production technology with that of your most significant competitors in Canada and outside of Canada?

Competitors Dthar Canadian producers DtA 1 2 3 4 5 Producers abroad Dia 1 2 3 4 5 Producers abroad Dia 1 2 3 4 5 Producers abroad Dia 0 1 2 3 4 5 Producers abroad Dia 0 1 2 3 4 5 Producers abroad Dia 0 1			Much less advanced	Less advanced	About the same	More advanced	Much more advanced
Other Canadian producers DA 1 2 3 4 5 7 Producers abroad Das 1 2 3 4 5 7 4 Did your firm engage in Research & Development activities in 1996?	Competitors			0	0	\sim	
Producers abroad DB 1 2 3 4 5 4 Did your firm engage in Research & Development activities in 1996? 1 Yes zp 2 No 5 Does your firm engage in R&D on a continuous or occasional basis?	Other Canadian produ	ICEIS D3A		2	3 ()	4 ()	5 🔾
4 Did your firm engage in Research & Development activities in 1996? 1 Yes 2 No 5 Does your firm engaged, in the year 1996, in alliances for R&D 1 Continuous 2 Occasional 6 Did your firm engaged, in the year 1996, in alliances for R&D 1 Ves 2 Occasional 7 If yes, please check the type of organizations and country of partner. 2 One partitions 3 Did your firm engage in R&D on a continuous or organizations and country of partner. 7 If yes, please check the type of organizations and country of partner. 2 One partners 2 Org 2 Org 2 Org 2 Org 3 3 4 4	Producers abroad	D3B	1 🔿	2	3 🔾	4 🔿	5 🔵
5 Does your firm engage in R&D on a continuous or cocasional basis? → 1 Continuous 2 Occasional continuous 6 Did your firm engaged, in the year 1996, in alliances for R&D purposes with other firms or organizations? → 1 Ves 2 2 Nc 7 If yes, please check the type of organizations and country of partner. Image: Competitors 2 Nc 5 Suppliers 074 072 Clients 076 076 Consultants 077 078 Other firms within group 0711 0712 Other firms not listed above 0711 0712 Government 0713 0714 University 0715 0716 Viewersity 0717 0718 Orments 0719 0719 Orments 0710 0714 Outreat firms not listed above 0717 0718 Orments 0719 0719	4 Did your firm engage i	n Research &De	velopment ad	ctivities in 1996?	\longrightarrow	1 () Yes 🎝	² 🔵 No
6 Did your firm engaged, in the year 1996, in alliances for R&D purposes with other firms or organizations? 	5 Does your firm engage occasional basis?	e in R&D on a co	ntinuous or	→	¹ O Continu	ous ²) Occasional
If yes, please check the type of organizations and country of partner. Canada Abroad Competitions 071 072 Suppliers 073 074 Clients 075 076 Consultants 077 078 Other firms within group 079 0710 Other firms not listed above 0711 0712 Government 0713 0714 University 0715 0716 Research Institutes 0717 0718	6 Did your firm engaged purposes with other fir	, in the year 1990 ms or organization	3, in alliances ons?	for R&D		¹ ○ Yes रू	2 🔿 No
Canada Abroad Competitors D71 D72 Suppliers D73 D74 Clients D75 D76 Consultants D77 D78 Other firms within group D79 D710 Other firms not listed above D711 D712 Government D715 D716 University D715 D716 Research Institutes D717 D718 Comments	7 If yes, please check th	ie type of organiz	ations and co	ountry of partner.		·	
Competitors D71 D72 Suppliers D73 D74 Clients D75 D76 Consultants D77 D78 Other firms within group D79 D710 Other firms not listed above D711 D712 Government D715 D716 University D715 D716 Research Institutes D717 D718					Canada	A	broad
Suppliers D73 D74 Suppliers D75 D76 Clients D77 D78 Other firms within group D79 D710 Other firms not listed above D711 D712 Other firms not listed above D711 D712 Government D715 D716 University D715 D716 Research Institutes D717 D718	Competitors			D71		D72	
Supprets D75 D76 Clients D77 D78 Consultants D77 D78 Other firms within group D79 D710 Other firms not listed above D711 D712 Government D713 D714 University D715 D716 Research Institutes D717 D718	Suppliers			D73		D74	
Clientis D77 D78 Consultants D79 D710 Other firms within group D71 D712 Other firms not listed above D711 D712 Government D713 D714 University D715 D716 Research Institutes D717 D718	Cliente			D75		D76	
Consultants D79 D710 Other firms within group D711 D712 Other firms not listed above D713 D714 Government D715 D716 University D717 D718	Clients			D77		D78	
Other firms within group D711 D712 Other firms not listed above D713 D714 Government D713 D714 University D715 D716 Research Institutes D717 D718	Consultants			D79		D710	
Other firms not listed above DT13 DT14 Government DT13 DT14 University DT15 DT16 Research Institutes DT17 DT18	Other firms within gro	oup		D711		D712	
Government D/13 D/14 University D/15 D/16 Research Institutes D/17 D/18	Other firms not listed	above		D710		D712	
University D715 D716 Research Institutes D717 D718	Government			D713		D714	
D717 D718 Comments	University			D715		D716	
Comments OTE : Should you have questions please contact your nearest Statistics Canada regional office. Image: Content of the image: Conten of the image: Content of the image: Conten of the i	Research Institutes			D717		D718	
DTE : Should you have questions please contact your nearest Statistics Canada regional office. Local Toll Free FAX Montréal 283-5724 1-800-363-6720 1-514-283-7969 Toronto 954-9072 1-800-565-2635 1-406-973-6524 Edmonton 495-4627 1-800-661-9884 1-403-495-4788	Comments						
DTE : Should you have questions please contact your nearest Statistics Canada regional office. Local Toll Free FAX Montréal 283-5724 1-800-363-6720 1-514-283-7969 Toronto 954-9072 1-800-565-2635 1-406-973-6524 Edmonton 495-4627 1-800-661-9884 1-403-495-4788							
DTE : Should you have questions please contact your nearest Statistics Canada regional office. Local Toll Free FAX Montréal 283-5724 1-800-363-6720 1-514-283-7969 Toronto 954-9072 1-800-565-2635 1-406-973-6524 Edmonton 495-4627 1-800-661-9884 1-403-495-4788							
DTE : Should you have questions please contact your nearest Statistics Canada regional office. Local Toll Free FAX Montréal 283-5724 1-800-363-6720 1-514-283-7969 Toronto 954-9072 1-800-565-2635 1-406-973-6524 Edmonton 495-4627 1-800-661-9884 1-403-495-4788							
DTE : Should you have questions please contact your nearest Statistics Canada regional office. Local Toll Free FAX Montréal 283-5724 1-800-363-6720 1-514-283-7969 Toronto 954-9072 1-800-565-2635 1-406-973-6524 Edmonton 495-4627 1-800-661-9884 1-403-495-4788							
DTE : Should you have questions please contact your nearest Statistics Canada regional office. Local Toll Free FAX Montréal 283-5724 1-800-363-6720 1-514-283-7969 Toronto 954-9072 1-800-565-2635 1-406-973-6524 Edmonton 495-4627 1-800-661-9884 1-403-495-4788							
DTE : Should you have questions please contact your nearest Statistics Canada regional office. Local Toll Free FAX Montréal 283-5724 1-800-363-6720 1-514-283-7969 Toronto 954-9072 1-800-565-2635 1-406-973-6524 Edmonton 495-4627 1-800-661-9884 1-403-495-4788							
DTE : Should you have questions please contact your nearest Statistics Canada regional office. Local Toll Free FAX Montréal 283-5724 1-800-363-6720 1-514-283-7969 Toronto 954-9072 1-800-565-2635 1-406-973-6524 Edmonton 495-4627 1-800-661-9884 1-403-495-4788							
Local Toll Free FAX Montréal 283-5724 1-800-363-6720 1-514-283-7969 Toronto 954-9072 1-800-565-2635 1-406-973-6524 Edmonton 495-4627 1-800-661-9884 1-403-495-4788							
LocalToll FreeFAXMontréal283-57241-800-363-67201-514-283-7969Toronto954-90721-800-565-26351-406-973-6524Edmonton495-46271-800-661-98841-403-495-4788	OTE - Should you have question	s please contact you		cs Canada regional	office		
Montréal 283-5724 1-800-363-6720 1-514-283-7969 Toronto 954-9072 1-800-565-2635 1-406-973-6524 Edmonton 495-4627 1-800-661-9884 1-403-495-4788	DTE : Should you have question	s please contact you	r nearest Statisti	cs Canada regional	office.		
Edmonton 495-4627 1-800-661-9884 1-403-495-4788	DTE : Should you have question	s please contact you	r nearest Statisti ɔcal	cs Canada regional	office.	AX	
	DTE : Should you have question	s please contact you Lo itréal 283	r nearest Statisti cal -5724	cs Canada regional Toll Free 1-800-363-6720	office. F. 1-514-2	AX 83-7969	